文献速递药物相互作用

强CYP2D6抑制剂对曲马多镇痛疗效的影响

Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors.
PubMed 文献 · Pharmacotherapy · 2019-05-20

结果显示联用强CYP2D6抑制剂者每日需更多突破性吗啡毫克当量(18.2±6.3 vs 5.7±6.7 mg,p<0.001),提示曲马多疗效临床相关下降。

要点

  • 联用强CYP2D6抑制剂时曲马多镇痛效果下降,需更多突破性阿片类药物。
  • 临床应审查用药清单,识别曲马多与强CYP2D6抑制剂的相互作用。
  • 必要时调整镇痛方案以确保充分疼痛控制。

核心结论

  • 接受强CYP2D6抑制剂的患者使用曲马多镇痛时,疗效出现临床相关下降。

主要发现

  • 联用强CYP2D6抑制剂者每日突破性吗啡毫克当量几何均值±SD为18.2±6.3 mg,未联用者为5.7±6.7 mg,p<0.001。
  • 两组平均疼痛评分、住院时长及曲马多停药率无显著差异。

临床怎么用

  • 临床医生应审查用药清单中曲马多与强CYP2D6抑制剂的联用情况,并相应调整方案以确保充分镇痛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Tramadol is metabolized by cytochrome P450 (CYP) 2D6 to form an active metabolite that exhibits its analgesic effect. Medications that inhibit this enzyme are used often in practice, yet the clinical impact of this interaction on the analgesic effects of tramadol has yet to be fully described. The objective was to determine whether a clinically relevant decrease in pain control is observed in patients taking scheduled tramadol concomitantly with a strong CYP2D6 inhibitor. DESIGN: Retrospective cohort study. SETTING: Large health care system. PATIENTS: One hundred fifty-two adult inpatients who received scheduled tramadol for at least 24 hours with (76 patients) or without (76 patients) a strong CYP2D6 inhibitor between January 1, 2012, and February 28, 2017, were included in the analysis. Patients hospitalized for opioid use disorder or those receiving substandard dosing of tramadol were excluded. MEASUREMENTS AND MAIN RESULTS: The primary outcome was mean breakthrough opiate consumption in the presence and absence of CYP2D6 inhibitors. Secondary outcomes included mean pain scores, length of hospital stay, tramadol discontinuation rates, and prespecified subgroup analyses based on patient sex, race, and specific CYP2D6 inhibitor administered. Patients receiving concurrent CYP2D6 inhibitors required significantly more breakthrough morphine milligram equivalents per day compared with patients receiving scheduled tramadol without CYP2D6 inhibitors (geometric mean ± SD 18.2 ± 6.3 vs 5.7 ± 6.7 mg morphine milligram equivalents, p<0.001). No significant differences existed between cohorts for mean pain score, length of hospital stay, or tramadol discontinuation rate. CONCLUSION: This study demonstrated a clinically relevant decrease in the efficacy of tramadol when used for pain control in patients receiving a strong CYP2D6 inhibitor. These results should encourage clinicians to review medication lists for this interaction and adjust regimens accordingly to ensure adequate pain control.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Frost DA, Soric MM, Kaiser R, et al. Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors. Pharmacotherapy. 2019. PMID: 31038218. doi:10.1002/phar.2269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。